IL240583A0 - Proprotein convertase subtilisin/kexin type 9 (pcsk9) allosteric binding ligands to mudulate serum low density lipoprotein (ldl) levels - Google Patents
Proprotein convertase subtilisin/kexin type 9 (pcsk9) allosteric binding ligands to mudulate serum low density lipoprotein (ldl) levelsInfo
- Publication number
- IL240583A0 IL240583A0 IL240583A IL24058315A IL240583A0 IL 240583 A0 IL240583 A0 IL 240583A0 IL 240583 A IL240583 A IL 240583A IL 24058315 A IL24058315 A IL 24058315A IL 240583 A0 IL240583 A0 IL 240583A0
- Authority
- IL
- Israel
- Prior art keywords
- mudulate
- pcsk9
- ldl
- levels
- low density
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/407—Liver; Hepatocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
- C12N9/6408—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361765423P | 2013-02-15 | 2013-02-15 | |
| US201361836381P | 2013-06-18 | 2013-06-18 | |
| PCT/US2014/016640 WO2014127316A2 (en) | 2013-02-15 | 2014-02-15 | Proprotein convertase subtilisin/kexin type 9 (pcsk9) allosteric binding ligands to mudulate serum low density lipoprotein (ldl) levels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL240583A0 true IL240583A0 (en) | 2015-09-24 |
Family
ID=51354696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL240583A IL240583A0 (en) | 2013-02-15 | 2015-08-13 | Proprotein convertase subtilisin/kexin type 9 (pcsk9) allosteric binding ligands to mudulate serum low density lipoprotein (ldl) levels |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2956154A4 (en) |
| JP (1) | JP2016508722A (en) |
| KR (1) | KR20150127622A (en) |
| CN (1) | CN105378159A (en) |
| AU (1) | AU2014216091A1 (en) |
| CA (1) | CA2901436A1 (en) |
| HK (1) | HK1219048A1 (en) |
| IL (1) | IL240583A0 (en) |
| SG (1) | SG11201506336XA (en) |
| WO (1) | WO2014127316A2 (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9273093B2 (en) | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
| ES2901704T3 (en) | 2013-03-15 | 2022-03-23 | Protagonist Therapeutics Inc | Hepcidin analogs and uses thereof |
| EP3960754A3 (en) | 2014-05-16 | 2022-07-06 | Protagonist Therapeutics, Inc. | Alpha4beta7 integrin thioether peptide antagonists |
| SG10201810154WA (en) | 2014-07-17 | 2018-12-28 | Protagonist Therapeutics Inc | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| EP3182971A4 (en) | 2014-08-21 | 2018-04-25 | SRX Cardio, LLC | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(pcsk9) protein activity |
| US10301371B2 (en) | 2014-10-01 | 2019-05-28 | Protagonist Therapeutics, Inc. | Cyclic monomer and dimer peptides having integrin antagonist activity |
| SG11201702553RA (en) | 2014-10-01 | 2017-04-27 | Protagonist Therapeutics Inc | NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS |
| MA41022A (en) * | 2014-11-24 | 2017-10-03 | Shire Human Genetic Therapies | LYSOSOMIAL TARGETING AND CORRESPONDING USES |
| US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| WO2017034994A1 (en) | 2015-08-21 | 2017-03-02 | Portola Pharmaceuticals, Inc. | Composition and methods of use of novel phenylalanine small organic compounds to directly modulate pcsk9 protein activity |
| US10865185B2 (en) | 2015-08-21 | 2020-12-15 | Srx Cardio, Llc | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity |
| US10568882B2 (en) | 2015-08-21 | 2020-02-25 | Srx Cardio, Llc | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use |
| US20180289843A1 (en) * | 2015-09-28 | 2018-10-11 | Agency For Science, Technology And Research | Coating for metal nanoparticles |
| CA3009834A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| WO2017147328A1 (en) | 2016-02-23 | 2017-08-31 | Portola Pharmaceuticals, Inc. | Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9) |
| CN115925790A (en) | 2016-03-23 | 2023-04-07 | 领导医疗有限公司 | Methods for synthesizing alpha 4 beta 7 peptide antagonists |
| EP3474875A1 (en) | 2016-06-24 | 2019-05-01 | H. Hoffnabb-La Roche Ag | Compositions and methods for treating cardiovascular disease |
| TW201823222A (en) * | 2016-12-23 | 2018-07-01 | 財團法人生物技術開發中心 | Compound, pharmaceutical composition and use thereof |
| US10278957B2 (en) | 2017-09-11 | 2019-05-07 | Protagonist Therapeutics, Inc. | Opioid agonist peptides and uses thereof |
| WO2019157268A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| CR20210441A (en) | 2019-01-18 | 2022-03-11 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| KR20220044277A (en) | 2019-07-10 | 2022-04-07 | 프로타고니스트 테라퓨틱스, 인코포레이티드 | Peptide inhibitors of interleukin-23 receptors and their use for treating inflammatory diseases |
| JP7441955B2 (en) | 2020-01-15 | 2024-03-01 | ヤンセン バイオテツク，インコーポレーテツド | Peptide inhibitors of interleukin-23 receptors and their use for treating inflammatory diseases |
| IL302996A (en) | 2020-11-20 | 2023-07-01 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of interleukin-23 receptor |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7928189B2 (en) * | 2008-05-05 | 2011-04-19 | Ottawa Health Research Institute | PCSK9 polypeptide fragment |
| CA2775413C (en) * | 2009-10-01 | 2015-03-17 | Cadila Healthcare Limited | Compounds for the treatment of dyslipidemia and related diseases |
| CN102206249B (en) * | 2011-04-26 | 2013-07-03 | 中国农业科学院哈尔滨兽医研究所 | Specific B cell epitope polypeptide of NS1 protein of encephalitis B virus and use thereof |
-
2014
- 2014-02-15 EP EP14751148.9A patent/EP2956154A4/en not_active Withdrawn
- 2014-02-15 WO PCT/US2014/016640 patent/WO2014127316A2/en active Application Filing
- 2014-02-15 KR KR1020157025152A patent/KR20150127622A/en not_active Application Discontinuation
- 2014-02-15 JP JP2015558178A patent/JP2016508722A/en active Pending
- 2014-02-15 CN CN201480017801.7A patent/CN105378159A/en active Pending
- 2014-02-15 SG SG11201506336XA patent/SG11201506336XA/en unknown
- 2014-02-15 CA CA2901436A patent/CA2901436A1/en not_active Abandoned
- 2014-02-15 AU AU2014216091A patent/AU2014216091A1/en not_active Abandoned
-
2015
- 2015-08-13 IL IL240583A patent/IL240583A0/en unknown
-
2016
- 2016-06-20 HK HK16107087.1A patent/HK1219048A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2901436A1 (en) | 2014-08-21 |
| CN105378159A (en) | 2016-03-02 |
| WO2014127316A4 (en) | 2014-12-04 |
| EP2956154A4 (en) | 2016-07-27 |
| WO2014127316A2 (en) | 2014-08-21 |
| WO2014127316A3 (en) | 2014-10-09 |
| HK1219048A1 (en) | 2017-03-24 |
| JP2016508722A (en) | 2016-03-24 |
| KR20150127622A (en) | 2015-11-17 |
| SG11201506336XA (en) | 2015-09-29 |
| EP2956154A2 (en) | 2015-12-23 |
| AU2014216091A1 (en) | 2015-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1219048A1 (en) | Proprotein convertase subtilisin/kexin type 9 (pcsk9) allosteric binding ligands to mudulate serum low density lipoprotein (ldl) levels /kexin 9 (pcsk9) (ldl) | |
| HK1243075A1 (en) | Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9) | |
| ZA201409210B (en) | Methods and uses for proprotein convertase subtilisin kexin 9 (pcsk9) inhibitors | |
| HK1257523A1 (en) | Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder | |
| HK1207592A1 (en) | Stable formulations containing anti-pcsk9 antibodies pcsk9 | |
| HK1216841A1 (en) | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9) 9(pcsk9) | |
| CO6910163A2 (en) | Methods for reducing lipoprotein levels (a) by administering a protein convertase subtilisin kexin-9 inhibitor (pcsk9) | |
| IL266066A (en) | Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction | |
| EP2968266A4 (en) | Anti-proprotein convertase subtilisin kexin type 9 (anti-pcsk9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases | |
| HK1202804A1 (en) | Treatment with anti-pcsk9 antibodies pcsk9 | |
| WO2012170607A3 (en) | Use of pcsk9 antagonists | |
| ZA201307499B (en) | Compositions and methods comprising serine protease variants | |
| MX2015016887A (en) | Methods fo inhibting atherosclerosis by administering an inhibitor of pcsk9. | |
| EP3182971A4 (en) | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(pcsk9) protein activity | |
| IL240437B (en) | Serum fraction of platelet-rich fibrin | |
| HK1213194A1 (en) | Novel binding proteins for pcsk9 pcsk9 | |
| HK1257102A1 (en) | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (pcsk9) modulators and their use | |
| FR2995225B1 (en) | MICROFLUIDIC SYSTEM HAVING A BED OF MAGNETIC PARTICLES | |
| SG11201510523QA (en) | Pump housing made of a magnetic and a non-magnetic material | |
| PL2682123T3 (en) | Biologically active food additive for normalizing the function of the thyroid gland | |
| GB201306127D0 (en) | Screen compounds for the modulation of proprotein convertase subtilisin/kexin type 9(pcsk9) | |
| HK1218140A1 (en) | Milk clotting aspartic protease enzyme composition | |
| GB201602153D0 (en) | Screen compounds for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) | |
| ZA201507890B (en) | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9) | |
| GB201107200D0 (en) | Methods of identifying FOXM1 ligands |